Maxim Group Lowers TuHURA Biosciences (NASDAQ:HURA) Price Target to $8.00

TuHURA Biosciences (NASDAQ:HURA) had its price objective decreased by research analysts at Maxim Group from $15.00 to $8.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price target indicates a potential upside of 269.52% from the company’s previous close.

HURA has been the topic of a number of other reports. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $10.33.

TuHURA Biosciences Stock Performance

Shares of TuHURA Biosciences stock traded up $0.13 during trading on Friday, hitting $2.17. 102,716 shares of the stock were exchanged, compared to its average volume of 279,687. The stock has a market cap of $110.97 million and a PE ratio of -1.26. The stock’s fifty day moving average is $2.46 and its 200 day moving average is $2.75. TuHURA Biosciences has a 12 month low of $1.80 and a 12 month high of $7.20.

TuHURA Biosciences (NASDAQ:HURA) last posted its earnings results on Friday, November 14th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01.

Institutional Trading of TuHURA Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Suncoast Equity Management grew its stake in TuHURA Biosciences by 4.4% in the second quarter. Suncoast Equity Management now owns 104,409 shares of the company’s stock valued at $233,000 after purchasing an additional 4,412 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $27,000. Intech Investment Management LLC acquired a new position in TuHURA Biosciences in the second quarter worth approximately $29,000. Invesco Ltd. bought a new position in TuHURA Biosciences during the second quarter valued at approximately $30,000. Finally, Merck & Co. Inc. acquired a new stake in TuHURA Biosciences in the second quarter valued at approximately $31,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.